F8 and hemophilia A: Using 2bF8 transgenic mice in the FVIII knockout background with varying VWF expressions, Shi et al. showed that both platelet-derived VWF and plasma-derived VWF are required for optimal platelet-derived FVIII gene therapy in hemophilia A mice with inhibitors (32).